Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored infliximab treatment based on trough levels in active luminal Crohn's disease
2011-003038-14Phase 4Completed
- Sponsor
- GETAID
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of infliximab in Crohn's disease (3 arms), sponsored by GETAID. Primary endpoint: Primary: Sustained steroid-free remission and endoscopic healing at week 54. Started Jan 2012; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2011-003038-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003038-14.